Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Rheumatoid Arthritis Age: Adult Condition: moderately-to-severely active rheumatoid arthritis in combination with methotrexate |
Dose: Subcutaneous solution – 50 mg Frequency: once monthly Note: in combination with methotrexate |
|
Indication: Rheumatoid Arthritis Age: Adult Condition: moderately-to-severely active rheumatoid arthritis in combination with methotrexate |
Dose: Intravenous solution – 2 mg/kg Frequency: at weeks 0 and 4, then every 8 weeks Note: in combination with methotrexate |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Moderately to severely active ulcerative colitis Age: 2 years of age and older |
Dose: Subcutaneous injection – 200 mg at Week 0, then 100 mg at Week 2, Week 6 and every 4 weeks thereafter Frequency: Every 4 weeks after induction Note: Subcutaneous injection |
|
Indication: Moderately to severely active ulcerative colitis Age: 2 years of age and older |
Dose: Subcutaneous injection – 100 mg at Week 0, then 50 mg at Week 2, Week 6 and every 4 weeks thereafter Frequency: Every 4 weeks after induction Note: Subcutaneous injection |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal impairment |
Dose: Not specified Note: No formal trial of the effect of renal or hepatic impairment on pharmacokinetics was conducted |
Administration
- For SC injection or IV infusion
- Allow to reach room temperature before use
Side Effect
- Upper respiratory tract infection (URTI)
- nasopharyngitis
- pharyngitis
- laryngitis
- rhinitis
- Upper respiratory tract infection (URTI)
- nasopharyngitis
- pharyngitis
- laryngitis
- rhinitis
- erythema
- urticaria
- induration
- pain
- bruising
- pruritus
- irritation
- paresthesia
- Viral infections (eg influenza and herpes) (5%)
- Increased ALT (4%)
- Increased AST (3%)
- Dizziness (2%)
- Paresthesia (2%)
- Bronchitis (2%)
- Superficial fungal infections (2%)
- Sinusitis (2%)
- Constipation (1%)
- Viral infections (eg influenza and herpes) (3%)
- Hypertension (2%)
- Rash (1%)
- Pyrexia (1%)
- Bronchitis (1%)
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Abatacept, anakinra, rituximab
|
Increased infection risk
|
|
Live-virus vaccines
|
May decrease humoral response
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
No specific contraindications listed
|
Monitor for general drug reactions
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Golimumab must be refrigerated at 2ºC to 8ºC and protected from light. Keep the product in the original carton to protect from light until the time of use. Do not freeze. Do not shake
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.